Olimab 60mg Dose | Injections | Applepharmaceuticals


OLIMAB 60MG


Description :

Olimab 60mg injection which attack and damage only certain cells in the body and help to protect healthy cells from demolish.
Olimab 60mg dose is a trade name of denosumab.
This medication is classified as a “bone-modifying agent”, it works as a RANK ligand (RANKL) inhibitor.

Olimab Used For :

Olimab 60mg is indicated to treat breast cancer in women whose taking certain treatment which make severe their risk of fractures and bone loss in men with prostate cancer.Olimab 60mg injection is indicated for the treatment of osteoporosis occur in and women (menopause stage) (end of menopause/ change of life), whose risk of fractures increased or who failed to other medication of osteoporosis.

Image result for bone cancer

Mechanism Of Action :

Denosumab is planning to aim RANKL (RANK ligand), a protein which work as the primary signal to help bone removal/resorption. In many bone loss conditions, RANKL overcome the body's natural defense against bone eradication. Denosumab inhibits RANKL from activating its receptor, RANK, which is on the surface of osteoclasts and their messengers. Prohibition of the RANKL/RANK interplay prevents osteoclast formation, function, and survival, Hence reducing bone resorption and raising bone mass and vitality in both cortical and trabecular bone.

Precautions

• Prior to start treatment with denosumab, consult with your doctor about any other regimens you are using (including over-the-counter drugs, vitamins, or herbal remedies). Not to take aspirin or products containing aspirin unless your doctor permits this.
• Olimab injection may improve the negative effects of immuno-suppressants. Especially the risk for severe infections may be raised. Inform your doctor of any immuno-suppressive drugs you early consume.
• Not to receive any type of vaccination without your doctor's consultation while admonishing denosumab.
• if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category C (use in pregnancy only if benefit to mother outweighs risk to fetus). Consult with doctor before the treatment
• Avoid breast feeding during Denosumab treatment.

Drug Interaction

No formal drug-drug interaction with denosumab during trials.
When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased

Pregnancy

The medication in pregnant women is contraindicated for use because it may cause serious risk to the fetus. The Olimab belongs to category C which has no enough data in pregnant women to convey any drug analog risk for adverse development outcomes.

Missed Dose :

Take the dose immediately before next dose duration
Next dose time reaches then left off the missed dose and continues regular schedule.
Avoid taking double dose at same time.
Please consult the doctor for further information.

For More Information : 

Call us :  +91-9987711567

Mail to : applepharmaceutical@gmail.com
 




Comments

Post a Comment

Popular posts from this blog

velasof, velasof tablets ,uses - Myapplepharma

VELASOF TABLETS DESCRIPTION : Velasof   is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects. DOSAGE BEFORE THE TREATMENT :  Care should be taken while using HCV medication in patients with HCV/HIV-1co infections, in this case HBV reactivation occurs.  Velasof   tablets are recommended for chronic condition of hepatitis C viral infection related to genotype 1, 2, 3, 4, 5 or 6. The dosing of  Velasof ; The usual recommended dose of  Velasof  is, one tablet should be administered orally as a single dose.  Velasof  tablet consist of 100mg of Velpatasvir & 400mg of Sofosbuvir.. WORKS AS :  This dynamic active moiety is get inserted into HCV RNA with the help of...
Read more

Today peoples are worried about NSLC – Xovoltib 30mg | Myapplepharma

  Xovoltib 30mg Description : Xovoltib 30mg is a prescription drugs which is used under the guidance of medical practioners. Xovoltib 30mg belongs to quinazoline and butanamide derivative which acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER. Indication : Xovoltib 30mg is indicated for treatment a certain type of lung cancer (non-small cell lung cancer) which has spread to other parts of the body. Mechanism : Xovoltib 30mg dose can blocking the activating sites called tyrosine kinases of various proteins within the cell.By stopping these targets, it will target the cancer will shrink.These proteins are most likely to develop cancer growth when the tumor includes the EGFR gene mutation. Precautions : Diarrhae: Most normal condition for people administrating this medications to have diarrhea. Certain situation this diarrhea can be serious. Severe diarrhea can c...
Read more

Sprycel 20mg tablet | Apple pharmaceuticals

Image
Sprycel 20mg Description : Sprycel 20mg belongs to oral dual BCR/ABL and Src group of tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main aim of Sprycel , are BCRABL, SRC, Ephrin’s and GFR. Sprycel 20mg is a prescription drug which used under the supervision of doctor. Indication : Sprycel 20mg   is indicated for the treatment of adult patients having chronic myeloid leukaemia. Sprycel 20mg is indicated for the treatment of adult patients having acute lymphoblastic leukaemia. DRUG INTERACTION :  Sprycel 20mg combination with CYP3A4 inducers will reduces Dasatinib plasma concentration. Sprycel 20mg combination with antacids will decrease Dasatinib plasma concentration. Sprycel 20mg combination with H2 antagonists/proton pump inhibitors will decrease Dasatinib plasma concentration. PRECAUTION :  Using of Sprycel will results in Tumor lysis syndrome; maintain sufficient hydration and correct ur...
Read more